相关实验视频
Updated: Mar 6, 2026

08:09
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
10.4K
作为一种新铁灭抑制剂的维里西瓜特减轻了多克索鲁比诱导的心脏毒性
Huiwen Han1,2,3,4, Tao Luo5,6, Canzhao Liu1,2,4,7
1Department of Cardiology, Heart Center, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Basic & clinical pharmacology & toxicology
|March 5, 2026
概括
维瑞西瓜特通过抑制关键细胞死亡途径铁亡,有效地治疗多克索鲁比诱导的心肌病变 (DIC). 这项研究凸显了 vericiguat作为一种有前途的治疗剂,用于预防化疗相关的心脏损伤.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 多克索鲁比化疗会引起剂量依赖性心脏毒性 (DIC).
- 目前没有针对DIC的特定疗法.
- 韦里西瓜特是一种可溶性瓜尼酸环酶激动剂,显示有心血管方面的益处.
研究的目的:
- 调查传送器在DIC中的作用.
- 阐明DIC中 vericiguat的分子机制,重点关注铁灭.
主要方法:
- 建立了体内 (小鼠) 和体内 (心肌细胞) DIC 模型.
- 评估心脏功能,心肌细胞活力,氧化应激和铁亡标志物 (铁,ROS,脂类过氧化物,SLC7A11,GPX4).
主要成果:
- 韦瑞西瓜特显著减少了多克索鲁比诱导的心脏损伤.
- 韦里西瓜特降低了氧化应激,并抑制了心肌细胞中的铁化.
- 韦里西瓜特抵消了埃拉斯诱导的心肌细胞损伤.
结论:
- 韦里西瓜特可以保护免受多克索鲁比诱导的心肌铁死.
- 维里西瓜特是DIC的潜在治疗候选药物.
- 韦里西瓜特作为一种新型铁灭抑制剂.
相关概念视频
Cardiomyopathy IV: Restrictive Cardiomyopathy
688
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
688
Heart Failure Drugs: Inotropic Agents
1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Cardiomyopathy III: Hypertrophic Cardiomyopathy
586
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
586
Cardiomyopathy II: Dilated Cardiomyopathy
685
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
685
Cardiomyopathy VI: Nursing Management
427
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
427
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K

